Compare SWKS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWKS | RDY |
|---|---|---|
| Founded | 1962 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.9B |
| IPO Year | 1995 | 2001 |
| Metric | SWKS | RDY |
|---|---|---|
| Price | $65.68 | $12.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $70.38 | $16.90 |
| AVG Volume (30 Days) | ★ 4.7M | 2.4M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.53% | 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $4,086,900,000.00 | N/A |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $3.06 | $3.50 |
| P/E Ratio | $68.04 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.93 | $11.36 |
| 52 Week High | $90.90 | $15.67 |
| Indicator | SWKS | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 45.35 |
| Support Level | $56.48 | $12.19 |
| Resistance Level | $67.67 | $12.58 |
| Average True Range (ATR) | 2.46 | 0.16 |
| MACD | -0.31 | 0.05 |
| Stochastic Oscillator | 40.82 | 33.90 |
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.